Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.
作者信息
Khan A Basit, English Collin W, Chen William C, Athukuri Prazwal, Bayley James C, Brandt Vicky L, Shetty Arya, Hadley Caroline C, Choudhury Abrar, Lu Hsiang-Chih, Harmanci Arif O, Harmanci Akdes S, Magill Stephen T, Raleigh David R, Klisch Tiemo J, Patel Akash J
机构信息
Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
出版信息
Acta Neuropathol. 2023 Apr;145(4):501-503. doi: 10.1007/s00401-023-02543-7. Epub 2023 Feb 2.
Abstract
摘要
相似文献
1
Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.即使CDKN2A/B杂合性缺失也会大大加速侵袭性脑膜瘤的复发。
Acta Neuropathol. 2023 Apr;145(4):501-503. doi: 10.1007/s00401-023-02543-7. Epub 2023 Feb 2.
2
Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.分析复发性和非复发性脑膜瘤中 CDKN2A 基因的改变。
J Neurooncol. 2019 Dec;145(3):449-459. doi: 10.1007/s11060-019-03333-6. Epub 2019 Nov 15.
3
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.CDKN2A/B纯合性缺失与脑膜瘤的早期复发相关。
Acta Neuropathol. 2020 Sep;140(3):409-413. doi: 10.1007/s00401-020-02188-w. Epub 2020 Jul 8.
4
Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.p16表达缺失是恶性脑膜瘤中CDKN2A纯合缺失的敏感标志物。
Acta Neuropathol. 2023 Apr;145(4):497-500. doi: 10.1007/s00401-023-02544-6. Epub 2023 Feb 1.
5
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.非典型性和间变性脑膜瘤中肿瘤抑制基因CDKN2A（p16(INK4a)）、p14(ARF)、CDKN2B（p15(INK4b)）和CDKN2C（p18(INK4c)）的改变。
Am J Pathol. 2001 Aug;159(2):661-9. doi: 10.1016/S0002-9440(10)61737-3.
6
CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.CDKN2A/B 缺失与脑膜瘤进展密切相关：一项个体患者数据的荟萃分析。
Acta Neuropathol Commun. 2023 Nov 28;11(1):189. doi: 10.1186/s40478-023-01690-y.
7
Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.CDKN2A 基因 mRNA 表达升高是临床侵袭性脑膜瘤的转录组学标志物。
Acta Neuropathol. 2023 Jul;146(1):145-162. doi: 10.1007/s00401-023-02571-3. Epub 2023 Apr 24.
8
Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature.伴有BRAF V600E突变的转移性横纹肌样脑膜瘤及对个体化治疗的良好反应：病例报告及文献复习
Pediatr Hematol Oncol. 2015 Apr;32(3):207-11. doi: 10.3109/08880018.2014.936058. Epub 2014 Aug 12.
9
Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.脑膜瘤进展过程中INK4a（p16-p14ARF）/INK4b（p15）表达的改变及端粒酶激活
J Neurooncol. 2001 Dec;55(3):149-58. doi: 10.1023/a:1013863630293.
10
Evolution to malignancy: A genetic stepwise study of tumor suppressor genes loss in a recurrent meningioma.向恶性肿瘤的演变：复发性脑膜瘤中肿瘤抑制基因缺失的遗传学逐步研究
Clin Neuropathol. 2015 Jul-Aug;34(4):237-9. doi: 10.5414/NP300839.
引用本文的文献
1
Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification.泛癌拷贝数分析确定了用于个体化风险分层的优化大小阈值和共现模型。
Nat Commun. 2025 Jul 2;16(1):6024. doi: 10.1038/s41467-025-61063-y.
2
Refining prognostic stratification of atypical meningiomas: significance of chromosome 1p deletion and brain invasion.优化非典型脑膜瘤的预后分层：1p染色体缺失和脑侵袭的意义
Acta Neuropathol Commun. 2025 Mar 6;13(1):50. doi: 10.1186/s40478-025-01973-6.
3
NF2 loss-of-function and hypoxia drive radiation resistance in grade 2 meningiomas.神经纤维瘤病2型功能丧失和缺氧导致2级脑膜瘤的放射抗性。
J Natl Cancer Inst. 2025 Jun 1;117(6):1175-1187. doi: 10.1093/jnci/djaf022.
4
Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis.典型扩增和CDKN2A/B缺失改善IDH1/2突变型星形细胞瘤的预后。
Neuro Oncol. 2025 May 15;27(4):993-1003. doi: 10.1093/neuonc/noae258.
5
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.cIMPACT-NOW更新8：脑膜瘤分子风险参数的澄清及世界卫生组织分级建议
Neuro Oncol. 2025 Feb 10;27(2):319-330. doi: 10.1093/neuonc/noae170.
6
The Impact of Molecular and Genetic Analysis on the Treatment of Patients with Atypical Meningiomas.分子与基因分析对非典型脑膜瘤患者治疗的影响
Diagnostics (Basel). 2024 Aug 15;14(16):1782. doi: 10.3390/diagnostics14161782.
7
Leveraging single-cell sequencing to classify and characterize tumor subgroups in bulk RNA-sequencing data.利用单细胞测序对批量 RNA 测序数据中的肿瘤亚群进行分类和特征分析。
J Neurooncol. 2024 Jul;168(3):515-524. doi: 10.1007/s11060-024-04710-6. Epub 2024 May 29.
8
Paired Primary and Recurrent Rhabdoid Meningiomas: Cytogenetic Alterations, Gene Expression Profile and Patient Outcome.配对的原发性和复发性横纹肌样脑膜瘤：细胞遗传学改变、基因表达谱及患者预后
Biology (Basel). 2024 May 16;13(5):350. doi: 10.3390/biology13050350.
9
The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.脑膜瘤不断演变的分类：整合分子发现以指导患者护理。
Cancers (Basel). 2024 Apr 30;16(9):1753. doi: 10.3390/cancers16091753.
10
Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas.基于 DNA 甲基化的组织学定义为 2 级脑膜瘤的综合分类的临床意义。
Acta Neuropathol Commun. 2024 May 8;12(1):74. doi: 10.1186/s40478-024-01739-6.
本文引用的文献
1
Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.脑膜瘤 DNA 甲基化组鉴定出生物学驱动因素和治疗脆弱性。
Nat Genet. 2022 May;54(5):649-659. doi: 10.1038/s41588-022-01061-8. Epub 2022 May 9.
2
Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies.多种方法汇聚于脑膜瘤的三种生物学亚型，并从已发表的研究中提取新的见解。
Sci Adv. 2022 Feb 4;8(5):eabm6247. doi: 10.1126/sciadv.abm6247. Epub 2022 Feb 2.
3
A clinically applicable integrative molecular classification of meningiomas.一种具有临床应用价值的脑膜瘤综合分子分类方法。
Nature. 2021 Sep;597(7874):119-125. doi: 10.1038/s41586-021-03850-3. Epub 2021 Aug 25.
4
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
5
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.CDKN2A/B纯合性缺失与脑膜瘤的早期复发相关。
Acta Neuropathol. 2020 Sep;140(3):409-413. doi: 10.1007/s00401-020-02188-w. Epub 2020 Jul 8.
6
Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.分析复发性和非复发性脑膜瘤中 CDKN2A 基因的改变。
J Neurooncol. 2019 Dec;145(3):449-459. doi: 10.1007/s11060-019-03333-6. Epub 2019 Nov 15.
7
Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors.分子谱分析预测脑膜瘤复发，并揭示侵袭性肿瘤中 DREAM 复合物抑制作用的丧失。
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21715-21726. doi: 10.1073/pnas.1912858116. Epub 2019 Oct 7.
8
SeSAMe: reducing artifactual detection of DNA methylation by Infinium BeadChips in genomic deletions.SeSAMe：减少基因组缺失中 Infinium BeadChips 检测到的 DNA 甲基化假阳性。
Nucleic Acids Res. 2018 Nov 16;46(20):e123. doi: 10.1093/nar/gky691.
9
Genomic landscape of high-grade meningiomas.高级别脑膜瘤的基因组图谱
NPJ Genom Med. 2017;2. doi: 10.1038/s41525-017-0014-7. Epub 2017 Apr 26.
10
Genomic landscape of intracranial meningiomas.颅内脑膜瘤的基因组景观。
J Neurosurg. 2016 Sep;125(3):525-35. doi: 10.3171/2015.6.JNS15591. Epub 2016 Jan 15.
Zotero 插件